FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2570153303> ?p ?o ?g. }

• W2570153303 abstract "We read with interest the article by Han et al., titled “Patterns of opioid use in sickle cell disease,” published in the American Journal of Hematology.1 The authors analyzed pain medication prescription records from a cohort of 203 patients with sickle cell disease (SCD), and found that the median (interquartile range) daily opioid dosage was 6.1 mg (1.7–26.3 mg) oral morphine equivalent (OMEQ), which is significantly lower than published opioid use among patients with other pain syndromes. The dose of opioids was found to be correlated with the number of admissions due to vasoocclusive crisis (VOC).1 We would like to commend the insightful work of Han et al., but we are very surprised by their finding that the median daily dose of only 6.1 mg oral morphine equivalent (OMEQ), considering the smallest dose of commercially available morphine pill is 15 mg, and patients with SCD tend to consume more opioids than many other chronic diseases. We wonder whether the results of their investigation truly reflect the “pattern” of chronic opioid in patients with SCD. Ballas et al.2 investigated the consumption of opioids at home, during acute care, and in the hospital, and found the opioids most commonly used at home were Oxycodone and Codeine followed by Meperidine and others. The mean oral daily dose for use at home was 15.5 mg (31 mg Morphine OMEQ) for Oxycodone, 79.8 mg (12 mg OMEQ) for Codeine, and 186.7 mg (18.7 mg OMEQ) for Meperidine. The mean parenteral daily dose during hospitalization was 523.4 mg (69.8 mg Morphine mEq) for Meperidine, 53.3 mg for Morphine, and 30.2 mg (201.3 mg Morphine mEq) for Hydromorphone,2 which would translate into 209.4 mg OMEQ (Meperidine), 159.9 mg OMEQ (morphine), and 603.9 mg OMEQ (hydromorphone), based on the routine conversion ratio of 1:3 from parental to oral administration. It is commonly accepted that SCD patients consume much more opioids during their VOC, when they receive treatment at Emergency Department (ED), especially when they are admitted to the hospital floor for the treatment of pain crisis. In the study of pattern of opioid usage in patients with SCD, Han et al. analyzed the results based on the prescribing records of adult SCD patients in its sickle cell care center at University of Illinois Hospital (UIH) only.1 In the Discussion section, authors did acknowledge some patients might obtain pain medication prescriptions upon hospital/ER discharge or from other institutions, and the UIH prescription records generally under-estimated use by approximately 40% in comparison with the dispensing records of the Illinois Prescription Monitoring Program. However, Han et al did not take into account the opioids consumed in ED or while inside the hospital, which, we believe, should be included for completeness to avoid any confusion by the healthcare providers and insurance carrier. We are concerned that if the median daily 6.1 mg opioid OMEQ gets misinterpreted or used as a norm in guiding pain management in patients with SCD, many patients who require higher amount of opioids may unfairly be deemed outliers. Ruta and Ballas3 recently expressed their concern that the current national opioid phobia may, unwittingly, deny opioids to patients who truly need them, especially those who experience recurrent exacerbations of acute pain such as patients with SCD. Suspicion and guilt, although rooted in concern and respect for the law, do not provide any solution to the complex problem.3 Drs. Fleegler and Schechter4 opined, “These are challenging times for clinicians who care for children and adults in pain. The general philosophy regarding the level of attention that should be paid to pain, as well as its treatment, has changed dramatically during the past 30 years, swinging wildly between extremes, and remains a moving target. Currently, most articles in the lay and even professional press highlight the problems associated with these drugs, as opposed to the significant benefits that may accrue from their appropriate use. As a result, at this time, we run the genuine risk of returning to a state of opiophobia and denying individuals in severe pain the mercy of access to these incredibly valuable drugs.” None." @default.
• W2570153303 created "2017-01-13" @default.
• W2570153303 creator A5035761162 @default.
• W2570153303 creator A5046522371 @default.
• W2570153303 creator A5046537879 @default.
• W2570153303 date "2017-02-03" @default.
• W2570153303 modified "2023-10-06" @default.
• W2570153303 title "A comment on pattern of opioid use in sickle cell disease" @default.
• W2570153303 cites W1610863995 @default.
• W2570153303 cites W2109004143 @default.
• W2570153303 cites W2414842969 @default.
• W2570153303 cites W2484292552 @default.
• W2570153303 doi "https://doi.org/10.1002/ajh.24643" @default.
• W2570153303 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28052380" @default.
• W2570153303 hasPublicationYear "2017" @default.
• W2570153303 type Work @default.
• W2570153303 sameAs 2570153303 @default.
• W2570153303 citedByCount "2" @default.
• W2570153303 countsByYear W25701533032017 @default.
• W2570153303 countsByYear W25701533032023 @default.
• W2570153303 crossrefType "journal-article" @default.
• W2570153303 hasAuthorship W2570153303A5035761162 @default.
• W2570153303 hasAuthorship W2570153303A5046522371 @default.
• W2570153303 hasAuthorship W2570153303A5046537879 @default.
• W2570153303 hasBestOaLocation W25701533031 @default.
• W2570153303 hasConcept C119060515 @default.
• W2570153303 hasConcept C126322002 @default.
• W2570153303 hasConcept C170493617 @default.
• W2570153303 hasConcept C1862650 @default.
• W2570153303 hasConcept C2776029756 @default.
• W2570153303 hasConcept C2776316548 @default.
• W2570153303 hasConcept C2777389121 @default.
• W2570153303 hasConcept C2777866328 @default.
• W2570153303 hasConcept C2781063702 @default.
• W2570153303 hasConcept C2781118164 @default.
• W2570153303 hasConcept C42219234 @default.
• W2570153303 hasConcept C71924100 @default.
• W2570153303 hasConceptScore W2570153303C119060515 @default.
• W2570153303 hasConceptScore W2570153303C126322002 @default.
• W2570153303 hasConceptScore W2570153303C170493617 @default.
• W2570153303 hasConceptScore W2570153303C1862650 @default.
• W2570153303 hasConceptScore W2570153303C2776029756 @default.
• W2570153303 hasConceptScore W2570153303C2776316548 @default.
• W2570153303 hasConceptScore W2570153303C2777389121 @default.
• W2570153303 hasConceptScore W2570153303C2777866328 @default.
• W2570153303 hasConceptScore W2570153303C2781063702 @default.
• W2570153303 hasConceptScore W2570153303C2781118164 @default.
• W2570153303 hasConceptScore W2570153303C42219234 @default.
• W2570153303 hasConceptScore W2570153303C71924100 @default.
• W2570153303 hasIssue "4" @default.
• W2570153303 hasLocation W25701533031 @default.
• W2570153303 hasLocation W25701533032 @default.
• W2570153303 hasOpenAccess W2570153303 @default.
• W2570153303 hasPrimaryLocation W25701533031 @default.
• W2570153303 hasRelatedWork W117028390 @default.
• W2570153303 hasRelatedWork W1920163842 @default.
• W2570153303 hasRelatedWork W2153052204 @default.
• W2570153303 hasRelatedWork W2170230856 @default.
• W2570153303 hasRelatedWork W2256080797 @default.
• W2570153303 hasRelatedWork W2941629973 @default.
• W2570153303 hasRelatedWork W2972340053 @default.
• W2570153303 hasRelatedWork W2977187351 @default.
• W2570153303 hasRelatedWork W2987001135 @default.
• W2570153303 hasRelatedWork W2994037982 @default.
• W2570153303 hasVolume "92" @default.
• W2570153303 isParatext "false" @default.
• W2570153303 isRetracted "false" @default.
• W2570153303 magId "2570153303" @default.
• W2570153303 workType "article" @default.